From T‐cell activation signals to signaling control of anti‐cancer immunity

Summary: The activation of resting T cells is crucial to most immune processes. Recognition of foreign antigen by T‐cell receptors has to be correctly translated into signal transduction events necessary for the induction of an effective immune response. In this review, we discuss the essential signals, molecules, and processes necessary to achieve full T‐cell activation. In addition to describing these key biological events, we also discuss how T‐cell receptor signaling may be harnessed to yield new therapeutic targets for a next generation of anti‐cancer drugs.

[1]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.

[2]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[3]  C. Baldari,et al.  F‐actin dynamics control segregation of the TCR signaling cascade to clustered lipid rafts , 2002, European journal of immunology.

[4]  B. Nal,et al.  Activation-induced polarized recycling targets T cell antigen receptors to the immunological synapse; involvement of SNARE complexes. , 2004, Immunity.

[5]  L. Harrington,et al.  Expanding the effector CD4 T-cell repertoire: the Th17 lineage. , 2006, Current opinion in immunology.

[6]  F. Alt,et al.  Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. , 2000, Immunity.

[7]  H Clevers,et al.  The T cell receptor/CD3 complex: a dynamic protein ensemble. , 1988, Annual review of immunology.

[8]  A. Weiss,et al.  The Syk family of protein tyrosine kinases in T‐cell activation and development , 1998, Immunological reviews.

[9]  J. Bluestone,et al.  CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301] , 1996, The Journal of experimental medicine.

[10]  M. Soloski.  Recognition of tumor cells by the innate immune system. , 2001, Current opinion in immunology.

[11]  A. Vella,et al.  Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. , 2005, Trends in immunology.

[12]  S. Burdach,et al.  ICOS: A New Costimulatory Ligand/Receptor Pair and Its Role in T-Cell Activion , 2004, Oncology Research and Treatment.

[13]  Emad S. Alnemri,et al.  CARD11 and CARD14 Are Novel Caspase Recruitment Domain (CARD)/Membrane-associated Guanylate Kinase (MAGUK) Family Members that Interact with BCL10 and Activate NF-κB* , 2001, The Journal of Biological Chemistry.

[14]  G. Courtois,et al.  Complementation Cloning of NEMO, a Component of the IκB Kinase Complex Essential for NF-κB Activation , 1998, Cell.

[15]  K. Tedford,et al.  Vav links antigen-receptor signaling to the actin cytoskeleton. , 1998, Seminars in immunology.

[16]  D. Moskophidis,et al.  TCR affinity and negative regulation limit autoimmunity , 2004, Nature Medicine.

[17]  D. Bowtell,et al.  Perturbed regulation of ZAP-70 and sustained tyrosine phosphorylation of LAT and SLP-76 in c-Cbl-deficient thymocytes. , 1999, Journal of immunology.

[18]  T. Okazaki,et al.  Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Mustelin,et al.  Dephosphorylation and activation of the T cell tyrosine kinase pp56lck by the leukocyte common antigen (CD45). , 1990, Oncogene.

[20]  F. Denizot,et al.  A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.

[21]  J. Penninger,et al.  cbl-3: a new mammalian cbl family protein , 1999, Oncogene.

[22]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Christoph Wülfing,et al.  Costimulation and endogenous MHC ligands contribute to T cell recognition , 2002, Nature Immunology.

[24]  E. Koonin,et al.  Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. , 2000, Molecular cell.

[25]  M. Naramura,et al.  Altered thymic positive selection and intracellular signals in Cbl-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Glant,et al.  Cutting Edge: Regulation of T Cell Activation Threshold by CD28 Costimulation Through Targeting Cbl-b for Ubiquitination1 , 2002, The Journal of Immunology.

[27]  T. Mak,et al.  Bimp1, a MAGUK Family Member Linking Protein Kinase C Activation to Bcl10-mediated NF-κB Induction* , 2001, The Journal of Biological Chemistry.

[28]  M. Cybulsky,et al.  Positive Regulation of T Cell Activation and Integrin Adhesion by the Adapter Fyb/Slap , 2001, Science.

[29]  Y. Liu,et al.  Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity , 2001, Cell.

[30]  Anjana Rao,et al.  Transcriptional Mechanisms Underlying Lymphocyte Tolerance , 2002, Cell.

[31]  A. Sharpe,et al.  The role of B7 co‐stimulation in activation and differentiation ofCD4+and CD8+T cells , 1998, Immunological reviews.

[32]  M. Seto,et al.  A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue , 1999, Oncogene.

[33]  Michael Loran Dustin,et al.  T Cell Receptor Signaling Precedes Immunological Synapse Formation , 2002, Science.

[34]  Yoji Shimizu,et al.  Coupling of the TCR to Integrin Activation by SLAP-130/Fyb , 2001, Science.

[35]  Morgan Huse,et al.  Agonist/endogenous peptide–MHC heterodimers drive T cell activation and sensitivity , 2005, Nature.

[36]  D. Cantrell,et al.  T cell activation and the cytoskeleton. , 2000, Annual review of immunology.

[37]  R. Baron,et al.  Leucine Zipper-mediated Homodimerization of the Adaptor Protein c-Cbl , 1999, The Journal of Biological Chemistry.

[38]  P. Bryant,et al.  Signaling pathways are focused at specialized regions of the plasma membrane by scaffolding proteins of the MAGUK family. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[39]  Chris Bakal,et al.  The MAGUK family protein CARD11 is essential for lymphocyte activation. , 2003, Immunity.

[40]  A. Levin,et al.  Effect of leukocytes on transplantability of human cancer. , 1967, Cancer.

[41]  K. Robbins,et al.  Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. , 1995, Oncogene.

[42]  K. Mills,et al.  Suppression of Antitumor Immunity by IL-10 and TGF-β-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells1 , 2006, The Journal of Immunology.

[43]  R. Steinman,et al.  Dendritic cells: translating innate to adaptive immunity. , 2006, Current topics in microbiology and immunology.

[44]  S. Bromley,et al.  The immunological synapse: a molecular machine controlling T cell activation. , 1999, Science.

[45]  Honglin Zhou,et al.  Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. , 2004, Nature.

[46]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[47]  Ivan Dikic,et al.  The Cbl interactome and its functions , 2005, Nature Reviews Molecular Cell Biology.

[48]  C. Figdor,et al.  On the mode of action of LFA-1. , 1990, Immunology today.

[49]  M. Davis,et al.  Low affinity interaction of peptide-MHC complexes with T cell receptors. , 1991, Science.

[50]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[51]  A. Mackensen,et al.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[52]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  M. Turner,et al.  The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kappaB pathways. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Colin R. F. Monks,et al.  Three-dimensional segregation of supramolecular activation clusters in T cells , 1998, Nature.

[55]  M. Callahan,et al.  Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice. , 2004, Journal of immunology.

[56]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[57]  J. Penninger,et al.  Phosphorylation and ubiquitination of the IκB kinase complex by two distinct signaling pathways , 2007, The EMBO journal.

[58]  Arup K Chakraborty,et al.  CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse , 2004, Nature Immunology.

[59]  C. Janeway,et al.  Innate Immunity: The Virtues of a Nonclonal System of Recognition , 1997, Cell.

[60]  C. Elly,et al.  Cbl-b, a RING-type E3 Ubiquitin Ligase, Targets Phosphatidylinositol 3-Kinase for Ubiquitination in T Cells* , 2001, The Journal of Biological Chemistry.

[61]  Xin-Yun Huang,et al.  Structural Basis for Relief of Autoinhibition of the Dbl Homology Domain of Proto-Oncogene Vav by Tyrosine Phosphorylation , 2000, Cell.

[62]  M. Seto,et al.  Bcl10 and MALT1, Independent Targets of Chromosomal Translocation in MALT Lymphoma, Cooperate in a Novel NF-κB Signaling Pathway* , 2001, The Journal of Biological Chemistry.

[63]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[64]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[65]  A. Iwasaki,et al.  Innate control of adaptive immunity: dendritic cells and beyond. , 2007, Seminars in immunology.

[66]  K. Horgan,et al.  The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. , 1990, Journal of immunology.

[67]  A. Altman,et al.  Protein kinase C(theta) in T cell activation. , 2002, Annual review of immunology.

[68]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[69]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[70]  J. Bluestone,et al.  Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. , 1997, Cancer research.

[71]  R. Zinkernagel,et al.  The discovery of MHC restriction. , 1997, Immunology today.

[72]  Lieping Chen,et al.  In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses , 2005, The Journal of experimental medicine.

[73]  C. Thompson,et al.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.

[74]  Lieping Chen,et al.  Cutting Edge: Cbl-b: One of the Key Molecules Tuning CD28- and CTLA-4-Mediated T Cell Costimulation1 , 2004, The Journal of Immunology.

[75]  S. Klinken,et al.  v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[76]  A. Duncan,et al.  Pleiotropic defects in TCR signaling in a Vav‐1‐null Jurkat T‐cell line , 2002, The EMBO journal.

[77]  Bernd Hinzmann,et al.  Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32) , 1999, Nature Genetics.

[78]  J. Ashwell,et al.  Cutting edge: the CD45 tyrosine phosphatase is an inhibitor of Lck activity in thymocytes. , 1999, Journal of immunology.

[79]  G. Baier.  The PKC gene module: molecular biosystematics to resolve its T cell functions , 2003, Immunological reviews.

[80]  C. Rudd.  Upstream-downstream: CD28 cosignaling pathways and T cell function. , 1996, Immunity.

[81]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[82]  M. Dyer,et al.  Bcl10 Is Involved in t(1;14)(p22;q32) of MALT B Cell Lymphoma and Mutated in Multiple Tumor Types , 1999, Cell.

[83]  M. Matsuda,et al.  Interleukin 10 pretreatment protects target cells from tumor- and allo- specific cytotoxic T cells and downregulates HLA class I expression , 1994, The Journal of experimental medicine.

[84]  S. Ghosh,et al.  Antigen-Receptor Signaling to Nuclear Factor κB , 2006 .

[85]  K. Tedford,et al.  The oncogene product Vav is a crucial regulator of primary cytotoxic T cell responses but has no apparent role in CD28‐mediated co‐stimulation , 1999, European journal of immunology.

[86]  M. Jenkins,et al.  Antigen presentation to naive CD4 T cells in the lymph node , 2003, Nature Immunology.

[87]  R. Hodes,et al.  Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. , 2007, The Journal of clinical investigation.

[88]  J. Penninger,et al.  Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. , 2004, Immunity.

[89]  Josef M. Penninger,et al.  CD45: new jobs for an old acquaintance , 2001, Nature Immunology.

[90]  L. Appleman,et al.  CD28 Costimulation Mediates Down-Regulation of p27kip1 and Cell Cycle Progression by Activation of the PI3K/PKB Signaling Pathway in Primary Human T Cells1 , 2002, The Journal of Immunology.

[91]  Yun-Cai Liu,et al.  Proteolysis-independent regulation of PI3K by Cbl-b–mediated ubiquitination in T cells , 2001, Nature Immunology.

[92]  G. Crabtree,et al.  NFAT Signaling Choreographing the Social Lives of Cells , 2002, Cell.

[93]  Dong-hai Wang,et al.  Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation. , 2005, Immunity.

[94]  Arthur Weiss,et al.  Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor , 1992, Cell.

[95]  Michael Loran Dustin,et al.  Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins , 2004, Nature Immunology.

[96]  M. Barbacid,et al.  Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+CDS+thymocytes , 1995, Nature.

[97]  Josef M. Penninger,et al.  Spontaneous tumor rejection by cbl-b–deficient CD8+ T cells , 2007, The Journal of experimental medicine.

[98]  K. Sugamura,et al.  Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 , 2004, Nature Reviews Immunology.

[99]  H. Ljunggren,et al.  Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. , 1997, Journal of immunology.

[100]  L. Samelson,et al.  Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. , 2002, Annual review of immunology.

[101]  O. Acuto,et al.  CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. , 2001, Immunity.

[102]  Michael Way,et al.  SLP-76 Coordinates Nck-Dependent Wiskott-Aldrich Syndrome Protein Recruitment with Vav-1/Cdc42-Dependent Wiskott-Aldrich Syndrome Protein Activation at the T Cell-APC Contact Site 1 , 2003, The Journal of Immunology.

[103]  D. Weisenburger,et al.  Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. , 1999, Cancer research.

[104]  Dirk Homann,et al.  Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory , 2001, Nature Medicine.

[105]  N. Abraham,et al.  Enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck , 1991, Nature.

[106]  R. Khokha,et al.  Cbl-3-Deficient Mice Exhibit Normal Epithelial Development , 2003, Molecular and Cellular Biology.

[107]  Y. Xiong,et al.  A role for NEMO/IKKγ Ubiquitination in the activation of the IκB kinase complex by TNF-α , 2003 .

[108]  K. Murphy,et al.  Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.

[109]  A. Rao,et al.  T cell differentiation: a mechanistic view. , 2000, Current opinion in immunology.

[110]  A. Weiss,et al.  Role of T3 surface molecules in human T-cell activation: T3-dependent activation results in an increase in cytoplasmic free calcium. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[111]  D. Franklin,et al.  An Important Role of CDK Inhibitor p18INK4c in Modulating Antigen Receptor-Mediated T Cell Proliferation1 , 2001, The Journal of Immunology.

[112]  S. Bromley,et al.  A supramolecular basis for CD45 tyrosine phosphatase regulation in sustained T cell activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[113]  D. Littman,et al.  Requirement for CARMA1 in Antigen Receptor-Induced NF-κB Activation and Lymphocyte Proliferation , 2003, Current Biology.

[114]  B. Sefton,et al.  Role of tyrosine kinases in lymphocyte activation. , 1994, Current opinion in immunology.

[115]  H. Nishina,et al.  Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b , 2000, Nature.

[116]  M. Nau,et al.  Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b , 2004, Oncogene.

[117]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[118]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[119]  P. Linsley,et al.  The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.

[120]  M. Thome.  CARMA1, BCL-10 and MALT1 in lymphocyte development and activation , 2004, Nature Reviews Immunology.

[121]  R H Wurtz,et al.  Optic flow: A brain region devoted to optic flow analysis? , 1998, Current Biology.

[122]  D. Kioussis,et al.  Vav1 Transduces T Cell Receptor Signals to the Activation of Phospholipase C-γ1 via Phosphoinositide 3-Kinase-dependent and -independent Pathways , 2002, The Journal of experimental medicine.

[123]  J. Penninger,et al.  Vav Regulates Peptide-specific Apoptosis in Thymocytes , 1998, The Journal of experimental medicine.

[124]  O. Rosnet,et al.  Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation , 1999, Oncogene.

[125]  Arup K Chakraborty,et al.  The Immunological Synapse Balances T Cell Receptor Signaling and Degradation , 2003, Science.

[126]  C. Thompson,et al.  Activation and inhibition of lymphocytes by costimulation. , 2002, The Journal of clinical investigation.

[127]  S. Ghosh,et al.  Antigen-receptor signaling to nuclear factor kappa B. , 2006, Immunity.

[128]  Keli Xu,et al.  Calcium oscillations increase the efficiency and specificity of gene expression , 1998, Nature.

[129]  H. Korn,et al.  Defective transmembrane calcium influx demonstrated in a primary immunodeficiency by video-imaging. , 1994, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[130]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[131]  C. Figdor,et al.  Avidity regulation of integrins: the driving force in leukocyte adhesion. , 2000, Current opinion in cell biology.

[132]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[133]  Jeanne Kowalski,et al.  Egr-2 and Egr-3 are negative regulators of T cell activation , 2005, Nature Immunology.

[134]  David J. Rawlings,et al.  Phosphorylation of the CARMA1 Linker Controls NF-κB Activation , 2005 .

[135]  Y. Xiong,et al.  A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. , 2003, The Journal of biological chemistry.

[136]  J. Bluestone,et al.  Regulation of CTLA-4 expression during T cell activation. , 1996, Journal of immunology.

[137]  F. Alt,et al.  Vav1 controls integrin clustering and MHC/peptide-specific cell adhesion to antigen-presenting cells. , 2002, Immunity.

[138]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[139]  Honglin Zhou,et al.  Bcl10 activates the NF-κB pathway through ubiquitination of NEMO , 2004, Nature.

[140]  J Bajorath,et al.  Immune regulation by CD40 and its ligand GP39. , 1996, Annual review of immunology.

[141]  Y. Xiong,et al.  A Role for NF-κB Essential Modifier/IκB Kinase-γ (NEMO/IKKγ) Ubiquitination in the Activation of the IκB Kinase Complex by Tumor Necrosis Factor-α* , 2003, Journal of Biological Chemistry.

[142]  J. Hutchcroft,et al.  CD28/CTLA-4 and CD80/CD86 families , 1999, Immunologic research.

[143]  M. Nau,et al.  Comparative genomic organization of the cbl genes. , 2003, Gene.

[144]  F. Garrido,et al.  MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.

[145]  F. Alt,et al.  Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene , 1995, Nature.

[146]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[147]  E. Shevach,et al.  Cbl-b regulates the CD28 dependence of T-cell activation , 2000, Nature.

[148]  Mark M Davis,et al.  T cells use two directionally distinct pathways for cytokine secretion , 2006, Nature Immunology.

[149]  N. Hogg,et al.  Vav1 transduces TCR signals required for LFA‐1 function and cell polarization at the immunological synapse , 2003, European journal of immunology.

[150]  K. Horgan,et al.  Roles of Adhesion Molecules in T‐Cell Recognition: Fundamental Similarities between Four Integrins on Resting Human T Cells (LFA‐1, VLA‐4, VLA‐5, VLA‐6) in Expression, Binding, and Costimulation , 1990, Immunological reviews.

[151]  C. Bakal,et al.  The Molecular Adapter Carma1 Controls Entry of IκB Kinase into the Central Immune Synapse , 2004, The Journal of experimental medicine.

[152]  A. Weiss.  Molecular and genetic insights into T cell antigen receptor structure and function. , 1991, Annual review of genetics.

[153]  F. Salazar-Onfray,et al.  Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. , 2007, Cytokine & growth factor reviews.

[154]  D. Olive,et al.  CD28 Utilizes Vav-1 to Enhance TCR-Proximal Signaling and NF-AT Activation1 , 2000, The Journal of Immunology.

[155]  F. Martinon,et al.  Carma1, a CARD‐containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF‐κB activation1 , 2001, FEBS letters.

[156]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[157]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[158]  J. Moon,et al.  Regulation of NF-κB Activation in T Cells via Association of the Adapter Proteins ADAP and CARMA1 , 2007, Science.

[159]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[160]  T. Mak,et al.  Bcl10 Is a Positive Regulator of Antigen Receptor–Induced Activation of NF-κ B and Neural Tube Closure , 2001, Cell.

[161]  K. Rajewsky,et al.  Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav , 1995, Nature.

[162]  X. Bustelo,et al.  Structural Determinants for the Biological Activity of Vav Proteins* , 2002, The Journal of Biological Chemistry.

[163]  S. Sugano,et al.  Molecular cloning and characterization of a novel cbl-family gene, cbl-c. , 1999, Gene.

[164]  Zhijian J. Chen,et al.  The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. , 2004, Molecular cell.

[165]  D. Bowtell,et al.  Tissue Hyperplasia and Enhanced T-Cell Signalling via ZAP-70 in c-Cbl-Deficient Mice , 1998, Molecular and Cellular Biology.

[166]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[167]  J. Wu,et al.  A functional T-cell receptor signaling pathway is required for p95vav activity , 1995, Molecular and cellular biology.

[168]  K. Tedford,et al.  Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor , 1998, Current Biology.

[169]  T. Honjo,et al.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.

[170]  S. Khoury,et al.  A critical role for the programmed death ligand 1 in fetomaternal tolerance , 2005, The Journal of experimental medicine.

[171]  A. Trautmann,et al.  ERM proteins regulate cytoskeleton relaxation promoting T cell–APC conjugation , 2004, Nature Immunology.

[172]  L. Cantley,et al.  Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx , 1985, Cell.

[173]  M. Callahan,et al.  Resistance to CD4+CD25+ Regulatory T Cells and TGF-β in Cbl-b−/− Mice , 2004, The Journal of Immunology.

[174]  G. Courtois,et al.  Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. , 1998, Cell.

[175]  Anjana Rao,et al.  Gene regulation mediated by calcium signals in T lymphocytes , 2001, Nature Immunology.

[176]  Roberto A. Maldonado,et al.  A role for the immunological synapse in lineage commitment of CD4 lymphocytes , 2004, Nature.

[177]  T. Honjo,et al.  Molecular mechanism of class switch recombination: linkage with somatic hypermutation. , 2002, Annual review of immunology.

[178]  A. Bandaranayake,et al.  Phosphorylation of the CARMA1 linker controls NF-kappaB activation. , 2005, Immunity.

[179]  K. Okumura,et al.  Blockade of B7-H1 on Macrophages Suppresses CD4+ T Cell Proliferation by Augmenting IFN-γ-Induced Nitric Oxide Production1 , 2005, The Journal of Immunology.

[180]  W. Langdon,et al.  Mini ReviewNegative regulation of PTK signalling by Cbl proteins , 2005, Growth factors.

[181]  A. Qattan,et al.  The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. , 2006, Neoplasia.

[182]  R. Flavell,et al.  Cutting Edge: Deficiency in the E3 Ubiquitin Ligase Cbl-b Results in a Multifunctional Defect in T Cell TGF-β Sensitivity In Vitro and In Vivo , 2006, The Journal of Immunology.

[183]  A. Mackensen,et al.  Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro , 2006, International journal of cancer.

[184]  W. Langdon,et al.  c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. , 2005, The Biochemical journal.